Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

allergies

Biogen Idec building

ICER says price of Biogen’s Aduhelm should be much lower

US cost-effectiveness watchdog’s analysis estimates current annual list price of $56,000 could be reduced to $3,000 to $8,400

- PMLiVE

ICER to review the role of health insurers in determining patient access to prescription drugs

Non-profit research institute will evaluate how health insurance policies may harm patient access to treatment

- PMLiVE

ICER extends evaluation of Biogen’s aducanumab after FDA delay

FDA delayed its decision on potential Alzheimer's therapy to 7 June

- PMLiVE

FDA knocks back DBV’s peanut allergy therapy once again

Drug loses further ground to Aimmune's Palforzia

- PMLiVE

AbbVie’s Rinvoq has ‘marginal clinical benefit’ over Humira at increased cost, says ICER

Updated draft evidence report maintains the benefit is small with higher price tag

- PMLiVE

Aimmune gets FDA panel backing for peanut allergy therapy

Step closer to becoming first approved treatment

- PMLiVE

ICER closely monitoring FDA’s Zolgensma investigation

Could affect initial cost assessment

- PMLiVE

Aimmune wins over ICER for peanut allergy product

Analysts predict blockbuster status for first-in-class

- PMLiVE

Aimmune preps EU filing for peanut allergy immunotherapy

Company set to be first to market

- PMLiVE

How to pay for very high cost, curative drugs? ICER and NICE put their heads together

Three HTA bodies seek answers to future value models

- PMLiVE

FDA gives breakthrough status to Xolair for food allergies

Food allergies could open up big new market for biologic

- PMLiVE

CGRP migraine drugs need prior approval for use, recommends ICER

Suggests clinicians should confirm that patients have tried other therapies prior to using CGRP inhibitors

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links